Meridian Bioscience price target raised to $24 from $22 at RW Baird Baird raised its price target on Meridian Bioscience following meeting with management. The firm believes investors sentiment is low but feels comfortable with guidance and management strategy for growth. Shares are Outperform rated.
News For VIVO From The Last 14 Days
Check below for free stories on VIVO the last two weeks.